Company Description
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.
It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer.
The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Marvin L. White |
Contact Details
Address: 2401 4th Ave., Suite 1050 Seattle, Washington 98121 United States | |
| Phone | 206-838-0500 |
| Website | aptevotherapeutics.com |
Stock Details
| Ticker Symbol | APVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671584 |
| CUSIP Number | 03835L207 |
| ISIN Number | US03835L2079 |
| Employer ID | 81-1567056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. White | President, Chief Executive Officer and Director |
| Jeffrey G. Lamothe CA | Executive Vice President and Chief Operating Officer |
| SoYoung Kwon J.D., LL.M. | Senior Vice President, General Counsel, Business Development and Corporate Affairs |
| Daphne L. Taylor | Senior Vice President and Chief Financial Officer |
| Dr. Dirk Huebner M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 424B4 | Prospectus |
| Apr 10, 2024 | EFFECT | Notice of Effectiveness |
| Apr 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 29, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 20, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 7, 2024 | 8-K | Current Report |